Pre-chemotherapy treatment delays return of aggressive lymphoma
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
Diagnosis & Disease Information
Engineered T cells help patients with relapsed B-ALL acheive remission
Treatment with autologous engineered T cells is effective bridge to potentially curative therapy
Melanoma uses weak immune cells to its advantage
Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response.
Ibrutinib may be a breakthrough for treatment of a rare lymphoma
Interim results confirmed the “unprecedented” single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
GVHD in pediatric HSCT patients: Clinical trials for Rituximab
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
Gene activity predicts course of chronic leukemia
A newly discovered molecular marker can distinguish aggressive chronic lymphocytic leukemia from a less aggressive form.
More chemotherapy might be best move for some children with leukemia
When induction therapy fails in acute lymphoblastic leukemia, some youths have better outcomes with more chemotherapy than with stem cell transplant.
Experimental agent acts against aggressive lymphoma subtype
The drug ibrutinib can provide significant anticancer responses with modest side effects in persons with diffuse large B-cell lymphomas (DLBCLs).
Survival improves for youths with leukemia
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia rose from 83.7% for 1990-1994 to 90.4% for 2000-2005.
Intensive chemotherapy greatly improved survival for lymphoma patients
Survival improved significantly for persons younger than 60 years with diffuse large B-cell lymphoma when they underwent intensified chemotherapy compared with the standard regimen.
- Loading...
Loading...
Loading... 
Loading...